To determine the serum concentrations of ranibizumab and vascular endothelial growth factor (VEGF) in infants with retinopathy of prematurity (ROP) who received intravitreal ranibizumab
Infants with ROP are studied. They received 0.25 mg or 0.5 mg of intravitreal ranibizumab to either 1 eye (unilateral cases) or both eyes (bilateral cases) with vascularly active ROP. Serum samples are collected 1 day before and 1 day, 3 days, 1 week after intravitreal ranibizumab. The serum concentrations of ranibizumab and VEGF are measured by enzyme-linked immunosorbent assay, and the changes of the serum VEGF levels are determined.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Enrollment
17
0.25 mg intravitreal ranibizumab to either 1 eye (unilateral cases) or both eyes (bilateral cases)
Xinhua Hospital
Shanghai, Shanghai Municipality, China
The effect of intravitreal ranibizumab on serum VEGF level
the changes of the serum VEGF levels
Time frame: 1 day before and 1 day, 3 days, 1 week after intravitreal ranibizumab
The effect of intravitreal ranibizumab on weight
measure weight of the infants
Time frame: corrected age of six month
The effect of intravitreal ranibizumab on height
measure height of the infants
Time frame: corrected age of six month
The effect of intravitreal ranibizumab on neurologic development
Gesell development diagnosis scale
Time frame: corrected age of six month
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.